OKYO Pharma stock maintains Buy rating at H.C. Wainwright on clinical trial plans

OKYO Pharma Ltd. (NASDAQ:OKYO) is advancing its lead candidate, urcosimod, for neuropathic corneal pain (NCP), announcing plans for a new ~100-patient multiple-ascending-dose trial following positive Phase 2 results. This trial aims to identify the optimal registration dose, with topline data anticipated in 2026, supported by the drug's FDA Fast Track designation and recent $1.9 million in non-dilutive funding. H.C. Wainwright reiterated its Buy rating and $7.00 price target, citing these developments and the significant unmet medical need in NCP, which currently lacks FDA-approved treatments.

Analysis

OKYO Pharma (NASDAQ:OKYO) is demonstrating significant clinical momentum for its lead drug candidate, urcosimod, for the treatment of neuropathic corneal pain (NCP). The company's plan to initiate a larger, approximately 100-patient multiple-ascending-dose trial is a critical step following positive top-line results from its initial 18-patient Phase 2 study. This new trial, with topline data anticipated in 2026, is designed to establish an optimal registration dose for future pivotal trials, a key de-risking milestone. The clinical program is further supported by an FDA Fast Track designation and $1.9 million in recent non-dilutive funding, which mitigates immediate shareholder dilution while financing development. H.C. Wainwright's reiterated Buy rating and $7.00 price target, representing substantial upside from the current $2.25 trading price, underscores analyst confidence. This positive outlook is amplified by the fact that there are currently no FDA-approved treatments for NCP, positioning urcosimod to address a significant unmet medical need if its clinical development is successful.

Key Decisions for Investors

• Investors with a high risk tolerance for clinical-stage biotechnology may view the positive Phase 2 data and clear development path as a compelling entry point, especially given the significant upside implied by the $7.00 analyst price target.
• It is critical to recognize the long-term and high-risk nature of this investment, as key topline data is not expected until 2026 and the outcome of clinical trials is inherently uncertain.
• Monitor key upcoming catalysts, including official trial initiation, the outcome of planned FDA meetings regarding registrational endpoints, and the company's cash runway relative to its clinical development costs.